Drug Trial Radar · NCT00378508
Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes
Last checked: Nov 20, 2026Latest source record: Aug 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
63
Actual
Start
Sep 2006
Primary completion
Aug 2011
Study completion Aug 2013
Sponsor
- Lead sponsor
- Yale UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Juvenile Diabetes Research Foundation
- First posted
- Sep 20, 2006
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 8 years, up to 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized placebo controlled study to test whether a single 14 course of treatment with the anti-CD3 monoclonal antibody, hOKT3gamma1(Ala-Ala),Teplizumab will prevent the loss of insulin secretory capacity in individuals with Type 1 diabetes of 4 - 12 months duration since diagnosis.
Conditions
- Type 1 Diabetes Mellitus
Interventions
mAb hOKT3gamma1(Ala-Ala), TeplizumabDrug
This is a randomized, two-arm, double blind placebo controlled phase II trial in which 60 participants with recent-onset T1DM are randomized at a 1:1 ratio to receive Teplizumab or placebo over a 14 day treatment period. The course of Teplizumab comprises daily doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, 413 µg/m2, and 10 of 826 µg/m2.
Placebo ArmDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- C-peptide Area Under the Curve (AUC) Response to a Mixed Meal Tolerance Test (MMTT) at 12 MonthsTime frame: At month 12 post-treatment
- C-peptide Area Under the Curve (AUC) Response to a Mixed Meal Tolerance Test (MMTT) at BaselineTime frame: At Baseline (before treatment)
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
University of California at San Francisco
San Francisco, California
Barbara Davis Diabetes Center
Aurora, Colorado
Yale University
New Haven, Connecticut
Children's Hospital of Philadelphia (CHOP)
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.